KRAS and neoplasm: LKB1 mutant/KRAS mutant NSCLCs showed significantly decreased tumor-associated macrophages, tumor-infiltrating lymphocytes, and PD-L1 expression and increased tumor-associated neutrophils compared to KRAS mutant only tumors (26).